Quanterix (QTRX) Competitors

Cytek Biosciences (NASDAQ:CTKB) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.

Which has more volatility and risk, CTKB or QTRX?

Cytek Biosciences has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.

Does the MarketBeat Community believe in CTKB or QTRX?

Quanterix received 250 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 61.68% of users gave Quanterix an outperform vote while only 45.83% of users gave Cytek Biosciences an outperform vote.

Company	Underperform	Outperform
Cytek Biosciences	Outperform Votes 22 45.83%	Underperform Votes 26 54.17%
Quanterix	Outperform Votes 272 61.68%	Underperform Votes 169 38.32%

Which has stronger valuation & earnings, CTKB or QTRX?

Cytek Biosciences has higher revenue and earnings than Quanterix. Cytek Biosciences is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$200.45M	2.37	-$12.15M	-$0.05	-74.20
Quanterix	$135.44M	1.65	-$28.35M	-$1.03	-5.59

Do analysts recommend CTKB or QTRX?

Cytek Biosciences presently has a consensus price target of $6.42, indicating a potential upside of 72.96%. Quanterix has a consensus price target of $16.20, indicating a potential upside of 181.25%. Given Quanterix's stronger consensus rating and higher possible upside, analysts clearly believe Quanterix is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quanterix	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Is CTKB or QTRX more profitable?

Cytek Biosciences has a net margin of -5.05% compared to Quanterix's net margin of -30.12%. Cytek Biosciences' return on equity of -2.58% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-5.05%	-2.58%	-2.05%
Quanterix	-30.12%	-11.74%	-9.66%

Does the media refer more to CTKB or QTRX?

In the previous week, Quanterix had 7 more articles in the media than Cytek Biosciences. MarketBeat recorded 13 mentions for Quanterix and 6 mentions for Cytek Biosciences. Quanterix's average media sentiment score of 1.09 beat Cytek Biosciences' score of 1.00 indicating that Quanterix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quanterix	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in CTKB or QTRX?

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 9.6% of Cytek Biosciences shares are owned by insiders. Comparatively, 6.9% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Cytek Biosciences and Quanterix tied by winning 9 of the 18 factors compared between the two stocks.